Full-Time

Senior Scientist II

Large Scale Biotherapeutic Purification

Posted on 8/29/2024

Generate Biomedicines

Generate Biomedicines

201-500 employees

Generates novel medicines using machine learning

Senior, Expert

Cambridge, MA, USA + 1 more

More locations: Andover, MA, USA

Role requires frequent travel between Somerville and Andover sites.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Minimum of 6+ years/PhD or 12+ years/MSc in a biotech/pharma industry setting.
  • Experience with standard chromatography methods in the Biotherapeutic Discovery and Development setting (Protein A, IEX, HIC, mixed mode, SEC).
  • Knowledge of how to implement QC requirements with a variety of downstream in-vitro and in-vivo uses.
  • Track record of using an array of analytical techniques to drive preparative workflows and define final product quality.
  • 3+ years of people management experience leading a team.
  • Excellent communication, attention to detail, documentation and technical writing skills.
  • Align with manufacturability from a purification perspective (e.g. resins, wash steps, flow though/weak partitioning, formulating).
Responsibilities
  • Guides rigorous data analysis, interpretation, and communication by monitoring and conducting complex data analysis and interpretation and ensuring high quality and reliability of data across multiple experimental data sets and projects.
  • Interpret complex data and providing guidance on troubleshooting challenging issues with the experiment; and leading the implementation of new digital tools or strategies.
  • Builds, coaches, and mentors a team of high-performing scientists by identifying and recommending new approaches and improvements that can be incorporated into development plans.
  • Lead and facilitate discussions with cross-functional teams on own lab or project team's work to drive success of multiple projects.
  • Guide multi-step protein purifications of various protein modalities leveraging different affinity tags, secondary chromatography and polishing steps on AKTA systems.
  • Assess protein quality metrics for all proteins produced within team.
  • Explore, assess, and bring in-house state of the art technologies to enhance and continuously improve efficiencies across internal platforms.
  • Manage all protein purification activities in group being accountable for planning, prioritization, and on-time delivery of generated protein variants.
  • Efficiently accomplish project goals on time and budget, tracking capacity constraints and resource use within team.
  • Collaborate and coordinate with upstream DNA and protein expression teams.
  • Encourage and help coordinate cross-training of sub-disciplines when appropriate.
  • Serve as a subject matter expert in recombinant protein production to different cross-functional teams.
  • Detailed documentation of experiments and data on our internal LIMS systems, electronic notebook and presentations to project teams.
  • Drive discussions with downstream stable CHO production groups for manufacturability.
  • Program leadership in the form of departmental representation.
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines focuses on creating new medicines using a method called generative biology, which combines machine learning and biological engineering. This approach involves analyzing millions of proteins to learn how nature encodes their functions, allowing the company to design new medicines with specific therapeutic effects. The main product, The Generate Platform, enables the rapid production of medicines across various therapeutic areas, significantly improving the drug discovery process compared to traditional methods. Unlike its competitors, Generate Biomedicines emphasizes a proactive and efficient approach to medicine creation, aiming to democratize access to biotherapeutics. The company's goal is to expand its capabilities in generating and testing proteins, with a commitment to developing innovative therapeutic solutions.

Company Size

201-500

Company Stage

Series C

Total Funding

$674.1M

Headquarters

Somerville, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Generative AI is enhancing Generate Biomedicines' drug discovery capabilities.
  • Strategic alliances, like with Novartis, leverage AI for drug development.
  • Samsung's investment indicates strong market confidence in Generate Biomedicines.

What critics are saying

  • Intellectual property disputes may arise as the generative biology platform expands.
  • Technological advancements may render current platforms obsolete without continuous innovation.
  • Reliance on partnerships could pose risks if collaborations don't meet expectations.

What makes Generate Biomedicines unique

  • Generate Biomedicines uses generative biology to create protein-based medicines efficiently.
  • The Generate Platform allows rapid production of medicines across multiple therapeutic areas.
  • The company integrates machine learning with biological engineering for innovative drug discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

1%
BioSpace
Jan 9th, 2025
Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference

Generate:Biomedicines provides update on its platform and pipeline powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire
Jan 9th, 2025
Generate:Biomedicines Provides Update On Its Platform And Pipeline Powered By Ai At The 43Rd Annual J.P. Morgan Healthcare Conference

SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an update on the company's platform, which combines generative AI and experimental innovation, and its advancing pipeline at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 7:30am PST. The Generate Platform has proven its ability to produce unique and differentiated molecules, allowing the company to advance multiple programs into clinical development and establishing programmable biology as a catalyst for new possibilities in medicine. "We are at the forefront of a biological revolution," said Mike Nally, CEO of Generate:Biomedicines. "Generative AI is enabling us to tackle some of the toughest challenges in drug discovery, from historically undruggable and hard-to-drug targets to optimizing molecules with unprecedented precision

PR Newswire
Dec 18th, 2024
Samsung Invests In Generate: Biomedicines To Advance Ai-Driven Protein Therapeutics Discovery

- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development- Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic developmentINCHEON, South Korea, Dec. 18, 2024 /PRNewswire/ -- Samsung announced today it has invested in Generate: Biomedicines ("Generate") as part of its efforts to drive growth and innovation in the biopharmaceutical sector. The investment was made via the Samsung Life Science Fund, which was created jointly between Samsung Biologics, Samsung C&T, and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.Generate, founded by Flagship Pioneering, is a US-based clinical stage company leading in generative biology. The company applies AI-based optimization and de novo generation to discover and design novel protein therapeutics, and has a robust pipeline of approximately 20 programs from preclinical to clinical development across oncology, immunology, and infectious diseases."We see great potential in Generate to develop first- and best-in-class therapeutics," said John Rim, President and CEO of Samsung Biologics. "Leveraging Generate's strengths in AI and machine learning, we look forward to creating an ecosystem for development, manufacturing, and R&D collaboration to advance next-generation medicines in areas with unmet needs.""Funding from leading partners like Samsung enables us to continue advancing our platform, generating high-quality data, and empowering our exceptional team to tackle some of the toughest challenges in human health," said Mike Nally, CEO of Generate:Biomedicines

Labiotech
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing

Pharma Industry Review
Sep 25th, 2024
Generate and Novartis Forge $1B+ Alliance for AI-Powered Protein Therapeutics

Beyond these high-profile partnerships, Generate also recently completed a $273 million Series C funding round, backed by key investors including Amgen and NVIDIA.

INACTIVE